BBNX — Beta Bionics, Inc. stock price, charts and financials

QT53Beta Bionics, Inc.

Beta Bionics, Inc. (NASDAQ: BBNX) is a Healthcare company in the Medical - Devices industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
16.75
+0.85+5.34%
OverviewShort InterestFilings
BBNXQT53Beta Bionics, Inc.·NASDAQ
16.75+5.34%
TA
Loading chart...
Signal & projected range
QT Score upgradeHistorical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Premium shows the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands ofhistorical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
CBLL+2.88%$19.35SSII-1.86%$3.70TCMD+0.34%$29.60AHCO-6.33%$5.33BWAY-1.10%$15.33SIBN+1.21%$18.84AVR+2.24%$9.11KIDS+1.45%$23.10
Snapshot
Index-P/E-EPS (ttm)-1.65Insider Own12.50%Shs Outstand44.99MPerf Week23.93%
Market Cap715.34MForward P/E-EPS next Y-2.15Insider Trans-1.34%Shs Float20.04MPerf Month-3.23%
Enterprise Value677.53MPEG7.70EPS next Q-0.57Inst Own-Short Float14.69%Perf Quarter51.43%
Income-73.68MP/S6.01EPS this Y-29.71%Inst Trans-Short Ratio6.72Perf Half Y20.09%
Sales119.01MP/B2.76EPS next Y-0.65%ROA-24.96%Short Interest6.61MPerf YTD-47.82%
Book/sh-P/C-EPS next 5Y-ROE-26.30%52W High34.46 -51.39%Perf Year4.61%
Cash/sh-P/FCF-EPS past 3/5Y-ROIC-30.98%52W Low9.27 80.68%Perf 3Y-
Dividend Est.-EV/EBITDA-Sales past 3/5Y-Gross Margin58.31%Volatility9.49% 8.26%Perf 5Y-
Dividend TTM-EV/Sales5.69EPS Y/Y TTM80.81%Oper. Margin-69.75%ATR (14)1.25Perf 10Y-
Dividend Ex-Date-Quick Ratio7.96Sales Y/Y TTM83.08%Profit Margin-61.32%RSI (14)54.19Recom2.25
Dividend Gr. 3/5Y-Current Ratio8.88EPS Q/Q-35.90%SMA201.12%Beta1.34Target Price19.83
Payout0.00%Debt/Eq0.03Sales Q/Q39.13%SMA505.24%Rel Volume1.18Prev Close15.90
Employees423LT Debt/Eq0.02EarningsOct 27SMA200-8.65%Avg Volume1.08MPrice16.75
IPO DateJan 30, 2025Option/ShortYes / YesEPS/Sales Surpr.8.78% 1.75%Net Debt/EBITDA0.53Volume1,274,254Change5.34%
Analyst Ratings
DateActionAnalystRatingTarget
Jul-28-26ResumedUBSBuy$24 → $22
Jul-15-26ReiteratedGoldman SachsBuy$17 → $19
Jul-13-26ReiteratedTruist SecuritiesBuy$25 → $22
May-27-26ReiteratedGoldman SachsBuy$25 → $17
Feb-18-26ReiteratedLake StreetBuy$40 → $20
Feb-18-26ReiteratedRobert W. Baird$28 → $14
Feb-18-26ReiteratedStifel Nicolaus$25 → $22
Feb-08-26InitiatedUBSBuy$24
Feb-04-26ReiteratedStifel Nicolaus$31 → $25
Feb-02-26ReiteratedTruist SecuritiesBuy$37 → $25
Latest News
Aug-03-26
Aug-03-2604:16AM
Beta Bionics, Inc. (NASDAQ:BBNX) Receives Average Rating of “Moderate Buy” from Analystsdefenseworld.net
Jul-31-26
Jul-31-2607:14PM
Beta Bionics, Inc. 2026 Q2 - Results - Earnings Call PresentationSeekingAlpha
Jul-30-26
Jul-30-2608:48AM
Beta Bionics Investor Alert: Johnson Fistel Reviews Potential Claims for Shareholdersglobenewswire.com
01:33AM
Beta Bionics, Inc. (BBNX) Q2 2026 Earnings Call Transcriptseekingalpha.com
Jul-29-26
Jul-29-2606:11PM
Beta Bionics, Inc. (BBNX) Reports Q2 Loss, Tops Revenue Estimateszacks.com
06:05PM
Beta Bionics Q2 Earnings Call Highlightsmarketbeat.com
04:02PM
Beta Bionics Announces Second Quarter 2026 Financial Results and Updates Full Year 2026 Guidanceglobenewswire.com
Jul-15-26
Jul-15-2612:46PM
Goldman Sachs Maintains Buy on Beta Bionics, Raises Price Target to $19Benzinga
Jul-13-26
Jul-13-2612:09PM
Truist Securities Maintains Buy on Beta Bionics, Raises Price Target to $22Benzinga
Jul-01-26
Jul-01-2611:28AM
Beta Bionics Investor Alert: Johnson Fistel Reviews Potential Claims for Shareholdersprnewswire.com
08:30AM
Beta Bionics to Announce Second Quarter 2026 Financial Results on July 29, 2026globenewswire.com
Jun-30-26
Jun-30-2609:08AM
Beta Bionics: Some Stabilization In SightSeekingAlpha
Company

Beta Bionics, Inc. is a commercial-stage medical technology company dedicated to inventing, developing, and bringing to market solutions that improve the health and quality of life for individuals with diabetes who depend on insulin. The company's flagship product, the iLet Bionic Pancreas, is an automated insulin delivery system currently available for treating type 1 diabetes in adults and children aged six and older. In addition to its existing offering, Beta Bionics is actively developing several new innovations: a Patch Pump, designed as a tubeless insulin pump that adheres directly to the skin; the Bihormonal iLet, which integrates automated delivery of both insulin and glucagon; and an iLet system specifically adapted for individuals with insulin-dependent type 2 diabetes. To support its product pipeline, the company has forged strategic alliances, including a collaboration and licensing agreement with Xeris Pharmaceuticals, Inc. to develop and commercialize a glucagon formulation compatible with pumps. It also holds a development and commercialization agreement with Abbott Diabetes Care Inc. for an automated insulin delivery system. Established in 2015, Beta Bionics is headquartered in Irvine, California.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
Total Revenue11910065——
Cost of Goods Sold Incl. D&A494529——
Gross Profit695636——
Selling, General and Administrative Excl. Other1139255——
Research and Development383526——
Other Operating Expense
100——
Operating Income-83-72-45——
Interest Expense
000——
Unusual Expense
—————
Non-Operating Income (Expense)10-2-10——
Net Income Before Taxes-72-73-55——
Income Taxes
000——
Consolidated Net Income-72-73-55——
Net Income From Continuing Operations-72-73-55——
Net Income-72-73-55——
EPS (Recurring)-1.68-1.81-1.28——
EPS (Basic, Before Extraordinaries)-1.68-1.81-1.28——
EPS (Diluted)-1.68-1.81-1.28——
EBITDA-72-70-54——
Other After Tax Adjustments
—————
Stock Option Compensation Expense
—————
Price To Earnings Ratio
—————
Price To Sales Ratio6.3312.49———
Gross Margin57.9856.0055.38——
Operating Margin-69.75-72.00-69.23——
Net Margin-60.50-73.00-84.62——
Shares Outstanding454143——
Market Capitalization7541,249———
Operating Lease Expense
—————
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
$35.46$27.94$20.42$12.91$5.39● Close Price0.00K223.99K447.98K671.97K895.96KUSD Trades VolumeAugSepOctNovDec2026FebMarAprMayJunJulAug
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Feider StephenChief Financial OfficerJun 29 '26Sale17.039,792166,762165,931Jul 02
Feider StephenChief Financial OfficerJun 29 '26Option Exercise5.109,79249,940170,949Jul 02
Feider StephenChief Financial OfficerJun 26 '26Option Exercise5.1010,08651,438171,157Jul 02
Feider StephenChief Financial OfficerJun 26 '26Sale17.0510,208174,012165,931Jul 02
Hopman MarkChief Commercial OfficerJun 24 '26Sale15.011,25818,880129,354Jun 25
Jones ChristyDirectorJun 24 '26Sale15.001,40621,09025,994Jun 25
Hopman MarkChief Commercial OfficerJun 04 '26Sale12.312753,385130,612Jun 05
Jones ChristyDirectorJun 04 '26Sale14.002,81139,35427,400Jun 05
Mensinger MikeChief Product OfficerJun 02 '26Sale12.614,37855,194184,415Jun 03
Hopman MarkChief Commercial OfficerJun 02 '26Sale12.615,32967,183130,887Jun 03
Russell Steven JonChief Medical OfficerJun 02 '26Sale12.614,22253,227173,849Jun 03
Feider StephenChief Financial OfficerJun 02 '26Sale12.616,67684,165166,053Jun 03
Saint SeanPresident & CEOJun 02 '26Sale12.6116,872212,707420,937Jun 03
Lezack AdamDirectorMay 22 '26Sale11.2199811,18827,399May 26
Jones ChristyDirectorMay 21 '26Sale9.951,99819,88013,246May 26
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.